Results 101 to 110 of about 3,831 (231)

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen, Rijing Zhou, Jie Fang, Jie Xiao   +3 more
wiley   +1 more source

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis

, 2018
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant ...
Kelly Peterson, Phung Nguyen, William J. Weiss, David Valtierra, David C. Griffith, Jerry W. Simecka, Mark E. Pulse, Mojgan Sabet, Jessica Silva   +8 more
core   +1 more source

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era [PDF]

, 2022
Gabriele Bianco, Matteo Boattini, Sara Comini, Roberto Casale, Marco Iannaccone, Rossana Cavallo, Cristina Costa   +6 more
openalex   +1 more source

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

Clinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg, Emily L. Heil, Suiyini Fiawoo, Jae Hyoung Lee, Sara E. Cosgrove, David M. Dobrzynski, Yihan Li, Ryan K. Shields, Emily S. Spivak, Erica J. Stohs, Pranita D. Tamma, Erin K. McCreary   +11 more
wiley   +1 more source

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates [PDF]

, 2021
Mariana Castanheira, Timothy B Doyle, Timothy D. Collingsworth, Hélio S. Sader, Rodrigo E. Mendes   +4 more
openalex   +1 more source

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

EFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ana Allende, Avelino Álvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Lieve Herman, Liesbeth Jacxsens, Lapo Mughini‐Gras, Maarten Nauta, Jakob Ottoson, Fernando Pérez‐Rodríguez, Panagiotis Skandamis, Elisabetta Suffredini, Hector Argüello, Johan Bengtsson‐Palme, Alessandra Carattoli, Anke Kohlenberg, Dominique L. Monnet, Laurent Poirel, Beatriz Guerra, Raquel García‐Fierro, Ernesto Liébana, Sonagnon Martin Goudjihounde, Núria Ferrer‐Bustins, Hanne Rabbås, Luisa Peixe   +28 more
wiley   +1 more source

Vaborbactam: perspective of a new β-lactamase inhibitor in the antimicrobial chemotherapy

, 2023
<p>Infections due to carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii constitute a global public health threat and are associated with high morbidity and mortality rates.
Koumaki, V., Amargianitaki, E., Papaparaskevas, J., Tsakris, A.   +3 more
core   +1 more source